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1064 The Journal of Thoracic and CardObjective: To overcome the shortcomings of current vascular grafts, tissue-
engineering methods have been applied to cardiovascular regions. We previously
reported the creation of a tissue-engineered vascular graft by using vascular mixed
cells. However, the cost and manpower for harvesting and culturing the cells was
too burdensome. To overcome these drawbacks, we have developed a new method
for creating a tissue-engineered vascular graft by using bone marrow cells, which
can be obtained easily and used immediately, without cell culture.
Methods: Biodegradable polymers seeded with different types of cells (group V,
cultured venous cells; group B, bone marrow cells without culture; and group C,
non–cell-seeded graft [as control]) were implanted into the inferior venae cavae of
dogs. The grafts were explanted at 4 weeks and assessed histologically and bio-
chemically.
Results: In the histologic examination, a regular layer of Masson-staining collagen
fiber and a layer of factor VIII–stained endothelial and anti–-smooth muscle cell
antigen–immunoreactive cells stained in groups V and B like native vascular tissue,
whereas no such stained regular lining was detected in group C. A 4-hydroxyproline
assay in group C showed significantly lower levels than in groups V and B or native
tissue (P  .05). The DNA content of the tissue-engineered vascular graft tended to
be higher in group C than in groups V and B or in native tissue.
Conclusions: In the creation of tissue-engineered vascular grafts, the method of
using bone marrow cells seems to be useful and superior to that of using vascular
cells because bone marrow cells can be used directly, without culture.
Many congenital heart defects are repaired by using vascular conduits suchas artificial vascular grafts. However, current artificial grafts carry sig-nificant limitations, including thrombosis, infection, limited durability,
and inability to grow in pediatric patients. In an attempt to overcome these short-
comings of current vascular devices, we previously reported the creation of tissue-
engineered vascular graft (TEVG) constructs by using cultured autologous vascular
wall cells seeded onto a synthetic biodegradable polymer scaffold.1,2 Autologous
TEVGs have the potential advantages of growth, durability, resistance to infection,
and freedom from the problems of rejection, thrombogenicity, and donor scarcity.
However, the use of the cultured vascular wall as a source of autologous cells for
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ETconstructing the TEVG has some disadvantages. First, the
number of easily accessible vessels that can be sacrificed is
limited. Second, vascular harvesting is distressing for the
patient. Third, culturing of the harvested cells requires much
time and expense. To overcome these disadvantages of
cultured vascular wall cells, we developed the new method
of using bone marrow, which can be easily obtained and
used immediately, without culture. This study was designed
to assess this new simple method of using bone marrow
cells (BMCs) compared with the previous method of using
vascular wall cells as the cell source to construct TEVGs.
Methods
Scaffold
The tissue scaffold was composed of a polyglycolic acid mesh
sheet sandwiched between 2 sheets of a copolymer of polylactic
acid and -caprolactone at a 50:50 ratio. The polymer matrix had
more than 80% porosity with a pore diameter of 20 to 50 m
before seeding. It loses its strength in approximately 16 weeks and
is degraded by hydrolysis in vivo after approximately 24 weeks
(not all data are shown). These polymers were fabricated into a
hybrid tubular scaffold 8 mm in diameter, 15 mm long, and 0.6
mm thick.
Cell Culture and Seeding
Venous cell group (group V; n  4). The techniques of
venous cell isolation, culture, and seeding have been described
previously in detail.2 In brief, 2- to 3-cm sections of the femoral
vein were harvested from 7- to 10-kg dogs, minced, and cultured
in GIT (Nihon Seiyaku Co, Tokyo, Japan) supplemented with 10%
fetal bovine serum (Moregate Biotech, Bulimba QLD, Australia),
2% anti–pleuropneumonia-like organism (PPLO, penicillin G 100
U/L (Life Technologies, Gaithersburg, Md), streptomycin 100
g/L (Life Technologies), recombinant human vascular endothe-
lial growth factor 1.0 g/L, recombinant human hepatocyte growth
factor 0.5 g/L, and recombinant human basic fibroblast growth
factor 2.5 g/L (Sigma Chemical Co, St Louis, Mo). The ex-
planted tissue culture was placed in a humidified incubator main-
tained at 37°C with 5% CO2 for 8 to 10 weeks. The culture
medium was changed every 3 to 4 days. Approximately 6 million
mixed cultured cells were seeded onto the polymer. The seeded
scaffold was incubated under similar conditions for 1 week.
BMC group (group B; n  4). Ten milliliters of BMCs was
harvested from the iliac bone of 7- to 10-kg dogs. Mononuclear
BMCs were separated from bone marrow with ficoil. In detail,
BMCs were aspirated into a syringe containing heparin (1000 U/10
mL of bone marrow). Three milliliters of whole bone marrow was
added to 3 mL of Histopaque-1077 (Sigma). After centrifugation at
400g for 30 minutes at room temperature, the layer of mononuclear
cells was carefully aspirated. All mononuclear cells (3.3  1.2 
106) were seeded onto the polymer immediately. The seeded
scaffold was kept in an incubator with culture media of RPMI-
1640 (Sigma) supplemented with 10% fetal bovine serum (More-
gate), 2% anti-PPLO, penicillin G 100 U/L (Life Technologies),
streptomycin 100 g/L (Life Technologies), recombinant human
vascular endothelial growth factor 1.0 g/L, recombinant human
hepatocyte growth factor 0.5 g/L, and recombinant human basic
The Journal of Thoracicfibroblast growth factor 2.5 g/L (Sigma) at 37°C with 5% CO2
for approximately 1 hour before implantation. The total number of
cells attached to the graft after 1 hour was 1.1 0.8 106 (Figure
1). 
Control group (group C; n 5). After 10 mL of bone marrow
was aspirated in the same method as group B to make the same
basic condition, the BMCs were discarded, and no cells were
seeded onto the polymer graft. This acellular polymer itself was
implanted as a control graft.
TEVG Replacement
Thirteen Beagle dogs were randomized into group V (n  4),
group B (n  4), and group C (n  5). Each TEVG was implanted
into the same dog from which the cells had previously been
harvested. Anesthesia was induced with thiopental and maintained
with propofol. The inferior vena cava was exposed through the
sixth right intercostal space. After heparin (0.1 mL/kg) was in-
jected, the TEVG was implanted into the inferior vena cava. The
Animal Care and Use Committee of Tokyo Women’s Medical
University approved the use of the animals.
Evaluation of TEVG
All animals were killed and the graft was explanted at 4 weeks
after implantation. The explanted graft and the adjacent native
venous tissue were evaluated macroscopically and histologically.
A portion of the specimen was fixed with 4% paraformalde-
hyde, sectioned, and stained with hematoxylin and eosin and
Masson trichrome stain for histologic examination. Additional
sections of the graft were also stained with immunohistochemical
techniques by using monoclonal antibodies to factor VIII (DAKO
Corporation, Carpinteria, Calif),3 anti–-smooth muscle actin
(DAKO), collagen type IV (DAKO), and CD31 (DAKO). The
other portion was immersed in 0.9% saline solution and immedi-
ately processed for collagen, calcium, and DNA assays. A 4-
Figure 1. The electronic microscope showed bone marrow cells
attached to the polymer.hydroxyproline assay4 was used to measure the collagen content in
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in the tissue. The orthocresolphthalein complexone method was
used for calcium measurement.6
Statistical Analysis
All results were analyzed with a statistical analysis software
package (StatView version 5; SAS Institute, Cary, NC). Anal-
ysis of variance and the Bonferroni test were used to analyze the
data. A probability value .05 was considered statistically
significant.
Results
Macroscopic Findings
In groups V and B, all TEVGs were patent and showed
complete endothelialization resembling native vessels. In
group C, only 2 (40%) of 5 grafts were patent. In patent
grafts, incomplete endothelialization and hard tissue were
observed. In all animals, the scaffold had been partially
biodegraded (Figure 2).
Histologic Examination
The TEVGs were removed at 4 weeks after implantation. A
regular layer of Masson stain showed evidence of collagen
in groups V and B, similar to native vascular tissue. How-
ever, group C showed an irregular layer of staining that was
different from native tissue (Figure 3). Immunohistochemi-
cally, groups V and B showed a layer of factor VIII–stained
endothelial cells lining the vascular surfaces, whereas no
such stained lining was detected in group C (Figure 4).
Groups V and B also showed an anti–-smooth muscle cell
Figure 2. In groups V and B, the TEVGs showed comple
In group C, incomplete endothelialization and hard tisantigen immunoreactive cell lining under the endothelium,
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In group B, immunohistochemical staining showed CD31-
positive endothelial cells and synthesis of type IV collagen
under the endothelial cell layer (Figure 6).
Biochemical Examination
A 4-hydroxyproline assay showed similar levels among
groups V and B and native tissue. These levels were sig-
nificantly lower in group C (P  .05; Figure 7). The DNA
content of the TEVGs tended to be a little higher in group
C than in groups V or B or native tissue (Figure 8). The
calcium content of these grafts was not significantly differ-
ent (Figure 9).
Discussion
Various types of vascular grafts are used for the surgical
treatment of cardiovascular disease. Tightly woven grafts
have been used because their low porosity was thought to be
preferable; however, these have the disadvantages of poor
neointima formation and tissue ingrowth, which promotes
calcification.7 In low-pressure circumstances or in small-di-
ameter vessels, these grafts also have a high risk of thrombo-
genesis. Cryopreserved homografts are subject to rejection and
have limited long-term durability. In addition, the supply of
cryopreserved homografts is greatly restricted.8
To address these shortcomings, efforts have been made
to develop an ideal viable conduit that is nonthrombogenic,
has growth potential, and will not ultimately require a
replacement operation. Previously there have been reports
dothelialization that resembled that of native vessels.
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ETand in the inferior vena cava of a dog model.2 In those
studies, the cells were attached to a biodegradable polymer
and continued to develop structurally. Subsequently, the
polymer degraded and left only the engineered tissue with-
Figure 3. Masson elastic stain showed evidence of e
vascular tissue. Group C showed an irregular layer of
tissue (original magnification, 40). BM, Bone marrow
Figure 4. Groups V and B showed a layer of factor V
whereas no such stained lining was detected in group C (
The Journal of Thoracicout any foreign material. As for the source of cells, vascular
mixed cells (consisting of vascular endothelial cells, myo-
fibroblasts, and vascular smooth muscle cells) harvested
from the carotid artery or femoral vein were used. These
n and collagen in groups V and B, similar to native
ic staining that was different from that seen in native
tained endothelial cells lining the vascular surfaces,lasti
elast
.III–s
original magnification, 100). BM, Bone marrow.
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mer before implantation.
However, TEVGs produced in this manner have some
disadvantages. First, the number of easily accessible vessels
that can be sacrificed is limited. Second, vascular harvesting
is distressing for the patient. Third, cell culture after har-
vesting the cells requires much time and expense.
In this study, these disadvantages were overcome by the
new method using BMCs—without long culture—as a
source of cells for seeding the scaffolds. Recent studies have
demonstrated that BMCs contain stem cells9 that have the
ability to differentiate into endothelial cells, smooth muscle
cells, or fibroblasts and then to proliferate.10 Furthermore, a
Figure 5. Groups V and B showed an anti–-smooth
endothelium, whereas no such layer was detected in
Figure 6. In group B, immunohistochemical staining sh
IV collagen under the endothelial cell layer.
1068 The Journal of Thoracic and Cardiovascular Surgery ● Maprosthetic vascular graft with infiltrated BMCs showed
complete endothelialization,11 and precursors of endothelial
cells with growth capacity12 were isolated from BMCs.13
Asahara and colleagues14 showed that endothelial progeni-
tor cells derived from bone marrow contributed to neovas-
cularization in a bone marrow transplantation model.
BMCs were able to form vascular tissues similar to those
of vascular mixed cells according to histologic and bio-
chemical assays in this study. These tissues included no
other structures, such as bone. In histologic studies, these
tissues were similar to native vascular tissues with regard to
the presence of a single layer of endothelial cells and the
arrangement of collagen fiber and smooth muscle cells. In
le cell antigen immunoreactive cell lining under the
C (original magnification, 100). BM, Bone marrow.
CD31-positive endothelial cells and synthesis of typemusc
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lower levels in the control groups than in others. These
results suggested that collagen formation was increased in
the cell-seeding groups (groups B and V), with no relation
to the type of cells, and that seeded cells on the scaffold had
an important role for vascular tissue formation through
unknown mechanisms. Matsumura and colleagues15 re-
ported that the seeded BMCs contribute to the creation of
TEVG. A little higher DNA content in the control group
might be attributed to the thrombosis and intimal hyperpla-
sia in the occluded grafts. Because the follow-up term of the
TEVG was short in this study, it might be difficult to detect
calcification in the graft.
In a comparison of methods for creating TEVGs, the
activity of seeding cells is an important factor. Because the
vascular cells were harvested in a simple explanted method,
there were few mixed vascular cells at first. After 4 to 6
Figure 7. A 4-hydroxyproline assay showed similar levels among
group V and B and native tissue. These levels were significantly
lower in group C (P < .05). BM, Bone marrow; Wg, wet · g.
Figure 8. The DNA content of the TEVGs tended to be higher in
group C than in groups V or B or native tissue. BM, Bone marrow;
N.S., not significant.
The Journal of Thoracicweeks, the number of culture cells increased to 1.0  106
mixed vascular cells. For seeding onto the polymer, we
detached these cultured cells from the flask by using trypsin.
Because the trypsin has some cytotoxicity, we cultured
these cells for 1 more week until their activity recovered.
With regard to the multipotential stem cells in bone marrow,
long culture might induce the differentiation to various
lineage cells. To keep the function and activity of the stem
cells, the culture period before implantation was limited to
1 hour.
Although TEVGs have many advantages, the current
TEVGs have several limitations, including high blood pres-
sure and small diameter. Because of the weakness of the
biodegradable polymer, it is difficult to use in high-pressure
conditions. In small-diameter grafts (less than 3 mm in
diameter), thrombosis often forms after implantation. In
addition, valved conduits are more difficult with the present
tissue-engineering technique because of its complex struc-
ture. To overcome these limitations, elucidation of a mech-
anism for creating engineered tissue might be important.
In conclusion, cell seeding onto the polymer is important
in the creation of TEVGs. Our results suggest that both
BMCs and vascular cells are appropriate as cell sources.
With regard to the methods of creating the TEVG, BMCs
may be superior to vascular cells because BMCs can be
used directly, without culture.
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